公开(公告)号：US20120251499A1

公开(公告)日：2012-10-04

申请号：US13514913

申请日：2010-09-08

申请人： Young Il Yeom ,  Bo Hwa Sohn ,  In Young Park ,  Jung Ju Lee ,  Yejin Jang ,  Suk-jin Yang ,  Kyung Chan Park ,  Hyang-sook Yoo ,  Jong Young Choi

发明人： Young Il Yeom ,  Bo Hwa Sohn ,  In Young Park ,  Jung Ju Lee ,  Yejin Jang ,  Suk-jin Yang ,  Kyung Chan Park ,  Hyang-sook Yoo ,  Jong Young Choi

IPC分类号： C12Q1/68 ,  A61K31/706 ,  A61P35/00 ,  A61K31/7068 ,  A61K38/02 ,  A61K31/713 ,  A61K31/7105

CPC分类号： C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/154

摘要： The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.

摘要翻译： 本发明涉及使用由TTP（Tristetraprolin）启动子中的特定单个CpG位点组成的表观遗传标记和通过调节其表观遗传学状态来治疗癌症来诊断和预后的方法。 特别地，本发明涉及通过测定由SEQ ID NO：1表示的核酸序列的第32个残基的C的特异性甲基化来诊断和预测肝癌的方法。 ID。 没有。 41，以及通过调节癌症治疗癌症的方法。 本发明可有效地用于诊断和/或治疗特征为TTP下调和甲基化的肝癌，即SEQ SEQ ID NO：1所示的核酸序列的第32个残基。 ID。 没有。 41.本发明可以进一步应用于以TTP下调和甲基化为特征的其他癌症或炎性疾病的诊断和治疗，C是SEQ ID NO：1所示的核酸序列的第32个残基。 ID。 没有。 41。

公开(公告)号：US08809295B2

公开(公告)日：2014-08-19

申请号：US13574055

申请日：2011-01-07

申请人： Kyung Chan Park ,  Young Il Yeom ,  Tae Woo Kim ,  Zee-Yong Park ,  Yun Kyung Kang ,  Suk-Jin Yang ,  Byung-Jung Choi ,  Dong Chul Lee ,  Hyun Ahm Shon ,  Hyang-Sook Yoo

发明人： Kyung Chan Park ,  Young Il Yeom ,  Tae Woo Kim ,  Zee-Yong Park ,  Yun Kyung Kang ,  Suk-Jin Yang ,  Byung-Jung Choi ,  Dong Chul Lee ,  Hyun Ahm Shon ,  Hyang-Sook Yoo

IPC分类号： C12N15/11 ,  C12N15/113 ,  A61K31/7105 ,  A61K31/7088

CPC分类号： A61K31/7088 ,  A61K31/7105 ,  C12N15/113 ,  C12N2310/14

摘要： The present invention relates to a composition comprising an inhibitor of the expression or activity of SH3 domain containing ring finger 2 (SH3RF2) for preventing or treating cancers. More specifically, since the SH3RF2 protein, of which the expression level increases in various cancer tissues, binds to PAK4, which is a cancer-associated gene, to regulate an apoptosis inhibitory function of the PAK4 protein by ubiquitination activity of SH3RF2 RING domain, cancer cells, in which the expression of SH3RF2 is inhibited, sensitively respond to the induction of apoptosis to promote apoptosis and reduce in vivo tumorigenicity, such that the inhibitor of the expression or activity of SHRF2 can be useful as a composition for preventing or treating cancers.

摘要翻译： 本发明涉及包含用于预防或治疗癌症的含有SH3结构域的SH3结构域（SH3RF2）的表达或活性抑制剂的组合物。 更具体地说，由于在各种癌组织中表达水平升高的SH3RF2蛋白与作为癌相关基因的PAK4结合以通过SH3RF2 RING结构域的泛素化活性调节PAK4蛋白的凋亡抑制功能，癌症 其中SH3RF2的表达被抑制的细胞对凋亡的诱导敏感应答以促进凋亡并降低体内致瘤性，使得SHRF2的表达或活性的抑制剂可用作预防或治疗癌症的组合物。

公开(公告)号：US08703419B2

公开(公告)日：2014-04-22

申请号：US13514913

申请日：2010-09-08

申请人： Young Il Yeom ,  Bo Hwa Sohn ,  In Young Park ,  Jung Ju Lee ,  Yejin Jang ,  Suk-jin Yang ,  Kyung Chan Park ,  Hyang-sook Yoo ,  Jong Young Choi

发明人： Young Il Yeom ,  Bo Hwa Sohn ,  In Young Park ,  Jung Ju Lee ,  Yejin Jang ,  Suk-jin Yang ,  Kyung Chan Park ,  Hyang-sook Yoo ,  Jong Young Choi

IPC分类号： C12N15/10

CPC分类号： C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/154

摘要： The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.

摘要翻译： 本发明涉及使用由TTP（Tristetraprolin）启动子中的特定单个CpG位点组成的表观遗传标记和通过调节其表观遗传学状态来治疗癌症来诊断和预后的方法。 特别地，本发明涉及通过测定由SEQ ID NO：1表示的核酸序列的第32个残基的C的特异性甲基化来诊断和预测肝癌的方法。 ID。 没有。 41，以及通过调节癌症治疗癌症的方法。 本发明可有效地用于诊断和/或治疗特征为TTP下调和甲基化的肝癌，即SEQ SEQ ID NO：1所示的核酸序列的第32个残基。 ID。 没有。 41.本发明可以进一步应用于以TTP下调和甲基化为特征的其他癌症或炎性疾病的诊断和治疗，C是SEQ ID NO：1所示的核酸序列的第32个残基。 ID。 没有。 41。

公开(公告)号：US20120321635A1

公开(公告)日：2012-12-20

申请号：US13574055

申请日：2011-01-07

申请人： Kyung Chan Park ,  Young Il Yeom ,  Tae Woo Kim ,  Zee-Yong Park ,  Yun Kyung Kang ,  Suk-Jin Yang ,  Byung-Jung Choi ,  Dong Chul Lee ,  Hyun Ahm Shon ,  Hyang-Sook Yoo

发明人： Kyung Chan Park ,  Young Il Yeom ,  Tae Woo Kim ,  Zee-Yong Park ,  Yun Kyung Kang ,  Suk-Jin Yang ,  Byung-Jung Choi ,  Dong Chul Lee ,  Hyun Ahm Shon ,  Hyang-Sook Yoo

IPC分类号： A61K39/395 ,  A61K31/713 ,  A61K31/7088 ,  A61K38/02 ,  C07K16/18 ,  C07H21/04 ,  C07K2/00 ,  G01N33/574 ,  G01N21/64 ,  C12Q1/68 ,  G01N33/573 ,  C12Q1/02 ,  A61P35/00 ,  C07H21/02

CPC分类号： A61K31/7088 ,  A61K31/7105 ,  C12N15/113 ,  C12N2310/14

摘要： The present invention relates to a composition comprising an inhibitor of the expression or activity of SH3 domain containing ring finger 2 (SH3RF2) for preventing or treating cancers. More specifically, since the SH3RF2 protein, of which the expression level increases in various cancer tissues, binds to PAK4, which is a cancer-associated gene, to regulate an apoptosis inhibitory function of the PAK4 protein by ubiquitination activity of SH3RF2 RING domain, cancer cells, in which the expression of SH3RF2 is inhibited, sensitively respond to the induction of apoptosis to promote apoptosis and reduce in vivo tumorigenicity, such that the inhibitor of the expression or activity of SHRF2 can be useful as a composition for preventing or treating cancers.

摘要翻译： 本发明涉及包含用于预防或治疗癌症的含有SH3结构域的SH3结构域（SH3RF2）的表达或活性抑制剂的组合物。 更具体地说，由于在各种癌组织中表达水平升高的SH3RF2蛋白与作为癌相关基因的PAK4结合以通过SH3RF2 RING结构域的泛素化活性调节PAK4蛋白的凋亡抑制功能，癌症 其中SH3RF2的表达被抑制的细胞对凋亡的诱导敏感应答以促进凋亡并降低体内致瘤性，使得SHRF2的表达或活性的抑制剂可用作预防或治疗癌症的组合物。